



GLAND PHARMA LIMITED

September 01, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245
Dear Sir/Madam,

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra
(East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Sub: Conclusion of USFDA Inspection at Company's VSEZ Sterile Oncology Formulations Facility and API Facility, Visakhapatnam

This is to inform you that the United States Food and Drug Administration (USFDA) has conducted a routine Good Manufacturing Practice (GMP) Inspection at the Company's VSEZ Sterile Oncology Formulations Facility and API Facility at Visakhapatnam between August 24, 2026 and September 01, 2026.

The said inspection was concluded with ZERO (0) Form 483 Observations.

The information required as per Regulation 30 read with Schedule III Para A Sub Para 20 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in **Annexure A** enclosed herewith.

Request to take the above information on record.

Yours truly,

For Gland Pharma Limited

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer

Encl: Annexure A

Annexure A

Sl. No	Particulars	Remarks
1	Name of the authority	United States Food and Drug Administration (USFDA)
2	Nature and details of the action(s) taken or order(s) passed;	Form 483 with Zero (0) Observations
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	September 01, 2026
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	Not Applicable
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	Not Applicable